4.4 Review

Differential molecular mechanistic behavior of HDACs in cancer progression

Journal

MEDICAL ONCOLOGY
Volume 39, Issue 11, Pages -

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12032-022-01770-4

Keywords

Cancer; Histone deacetylases; Metastasis; Stemness potential; Angiogenesis; Metabolism

Categories

Funding

  1. Council of Scientific and Industrial Research (CSIR), New Delhi
  2. DST FIST [SR/FST/LS-I/2017/49]
  3. Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda

Ask authors/readers for more resources

Genetic aberration and epigenetic modifications play important roles in cancer development. HDACs, a type of histone modifier, regulate various aspects of cell survival, apoptosis, and metastasis, and are considered potential targets for anti-cancer drug development.
Genetic aberration including mutation in oncogenes and tumor suppressor genes transforms normal cells into tumor cells. Epigenetic modifications work concertedly with genetic factors in controlling cancer development. Histone acetyltransferases (HATs), histone deacetylases (HDACs), DNA methyltransferases (DNMTs) and chromatin structure modifier are prospective epigenetic regulators. Specifically, HDACs are histone modifiers regulating the expression of genes implicated in cell survival, growth, apoptosis, and metabolism. The majority of HDACs are highly upregulated in cancer, whereas some have a varied function and expression in cancer progression. Distinct HDACs have a positive and negative role in controlling cancer progression. HDACs are also significantly involved in tumor cells acquiring metastatic and angiogenic potential in order to withstand the anti-tumor microenvironment. HDACs' role in modulating metabolic genes has also been associated with tumor development and survival. This review highlights and discusses the molecular mechanisms of HDACs by which they regulate cell survival, apoptosis, metastasis, invasion, stemness potential, angiogenesis, and epithelial to mesenchymal transitions (EMT) in tumor cells. HDACs are the potential target for anti-cancer drug development and various inhibitors have been developed and FDA approved for a variety of cancers. The primary HDAC inhibitors with proven anti-cancer efficacy have also been highlighted in this review.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available